Xu‐Feng Zhang, Xinping Tan, Gang Zeng, Amalea Misse, Sucha Singh, Youngsoo Kim, James E. Klaunig, Satdarshan P. S. Monga – 26 August 2010 – Activation of β‐catenin, the central effector of the canonical Wnt pathway and a recognized oncogene, has been implicated in hepatocellular carcinoma. We examined N‐nitrosodiethylamine (DEN)‐induced tumorigenesis in hepatic β‐catenin conditional knockout mice (β‐cat KO). Male β‐cat KO and age‐ and sex‐matched littermate controls were given a single intraperitoneal DEN injection and followed for 6‐12 months for hepatic tumors.

Rohit Kohli, Michelle Kirby, Stavra A. Xanthakos, Samir Softic, Ariel E. Feldstein, Vijay Saxena, Peter H. Tang, Lili Miles, Michael V. Miles, William F. Balistreri, Stephen C. Woods, Randy J. Seeley – 26 August 2010 – Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans.

Darmendra Ramcharran, Abdus S. Wahed, Hari S. Conjeevaram, Rhobert W. Evans, Tianyi Wang, Steven H. Belle, Leland J. Yee, for the Virahep‐C Study Group – 26 August 2010 – Approximately one half of patients who undergo antiviral therapy for chronic hepatitis C virus (HCV) genotype 1 infection do not respond to treatment. African Americans (AAs) are less responsive to treatment than Caucasian Americans (CAs), but the reasons for this disparity are largely unknown. Recent studies suggest that serum lipids may be associated with treatment response.

Stephen A. Harrison, Lorenzo Rossaro, Ke‐Qin Hu, Keyur Patel, Hans Tillmann, Sandeep Dhaliwal, Dawn M. Torres, Kenneth Koury, Venkata S. Goteti, Stephanie Noviello, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Mark S. Sulkowski – 26 August 2010 – Elevated low‐density lipoprotein (LDL) levels and statin use have been associated with higher sustained virological response (SVR) rates in patients receiving chronic hepatitis C therapy. However, these relationships have not been well characterized in randomized controlled trials.

Katrina J. Allen, Nadine A. Bertalli, Nicholas J. Osborne, Clare C. Constantine, Martin B. Delatycki, Amy E. Nisselle, Amanda J. Nicoll, Dorota M. Gertig, Christine E. McLaren, Graham G. Giles, John L. Hopper, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Lyle C.

Federico Salamone, Fabio Galvano, Giovanni Li Volti – 26 August 2010

Maureen M. Jonas, Joan M. Block, Barbara A. Haber, Saul J. Karpen, W. Thomas London, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Kathleen B. Schwarz, Brian J. McMahon – 25 August 2010 – Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited number of drugs that have been studied in children.

Julien Villeneuve, Sébastien Lepreux, Audrey Mulot, Annie M. Bérard, Arisa Higa‐Nishiyama, Pierre Costet, Victor De Ledinghen, Paulette Bioulac‐Sage, Charles Balabaud, Alan T. Nurden, Jean Rosenbaum, Eric Chevet, Jean Ripoche – 25 August 2010 – Inflammation and lipid metabolism pathways are linked, and deregulation of this interface may be critical in hepatic steatosis. The importance of the dialog between inflammatory signaling pathways and the unfolded protein response (UPR) in metabolism has been underlined.

Bijan Raziorrouh, Winfried Schraut, Tilman Gerlach, Daniela Nowack, Norbert H. Grüner, Axel Ulsenheimer, Reinhart Zachoval, Martin Wächtler, Michael Spannagl, Jürgen Haas, Helmut M. Diepolder, Maria‐Christina Jung – 25 August 2010 – Multiple inhibitory receptors may play a role in the weak or absent CD8+ T‐cell response in chronic hepatitis B virus (HBV) infection. Yet few receptors have been characterized in detail and little is known about their complex regulation.

23 August 2010